Quest Diagnostics is turning a scale lab business into a high-complexity, information-driven diagnostics platform—powered by advanced testing, hospital partnerships, and digital modernization—while still delivering defensive, mid-teens margins.
Overview
Quest Diagnostics’ Q1 2026 results demonstrate that its multi-year transformation is translating into measurable financial acceleration. Revenue rose to $2.90B (+9.2% YoY; ~9.0% organic), driven primarily by requisition volume growth of ~10.9% (10.8% organic), reflecting stronger utilization, expanded health-plan access, and hospital collaborative contributions. Despite a modest decline in revenue per requisition (-1.3%) from mix and early-stage hospital integration economics, operating income increased 15.5% to $399M, with operating margin expanding to 13.8% (adjusted margin 15.4%), supported by SG&A leverage and productivity initiatives. Management raised FY2026 guidance across revenue and EPS, reinforcing confidence that growth engines—advanced diagnostics (notably oncology MRD and Alzheimer’s blood biomarkers), Co-Lab hospital partnerships, and consumer testing—are more than offsetting investment headwinds such as Project Nova/Epic modernization. With payer access now exceeding 90% of in-network lives and a large-scale digital and operational upgrade underway, Quest is positioning itself as a ‘defensive growth’ compounder in an ~$90B U.S. lab market.